JP2015509085A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509085A5
JP2015509085A5 JP2014549632A JP2014549632A JP2015509085A5 JP 2015509085 A5 JP2015509085 A5 JP 2015509085A5 JP 2014549632 A JP2014549632 A JP 2014549632A JP 2014549632 A JP2014549632 A JP 2014549632A JP 2015509085 A5 JP2015509085 A5 JP 2015509085A5
Authority
JP
Japan
Prior art keywords
composition
antibody
endo180
antigen
lipid particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014549632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2012/000405 external-priority patent/WO2013098813A1/en
Publication of JP2015509085A publication Critical patent/JP2015509085A/ja
Publication of JP2015509085A5 publication Critical patent/JP2015509085A5/ja
Pending legal-status Critical Current

Links

JP2014549632A 2012-01-01 2012-12-31 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子 Pending JP2015509085A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261582373P 2012-01-01 2012-01-01
US61/582,373 2012-01-01
PCT/IL2012/000405 WO2013098813A1 (en) 2012-01-01 2012-12-31 Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents

Publications (2)

Publication Number Publication Date
JP2015509085A JP2015509085A (ja) 2015-03-26
JP2015509085A5 true JP2015509085A5 (OSRAM) 2016-02-18

Family

ID=47681993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549632A Pending JP2015509085A (ja) 2012-01-01 2012-12-31 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子

Country Status (7)

Country Link
US (1) US20150216998A1 (OSRAM)
EP (1) EP2797632A1 (OSRAM)
JP (1) JP2015509085A (OSRAM)
CN (1) CN104080480A (OSRAM)
CA (1) CA2858336A1 (OSRAM)
SG (1) SG11201403756PA (OSRAM)
WO (1) WO2013098813A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
US9925143B2 (en) 2012-04-18 2018-03-27 Ramot At Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2015198326A1 (en) 2014-06-26 2015-12-30 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
HRP20191400T1 (hr) * 2014-12-24 2019-11-15 Aadigen Llc Peptidi i nanočestice za unutarstaničnu isporuku molekula
KR20170104550A (ko) * 2015-01-14 2017-09-15 엑시큐어, 인크. 코어 모티프를 갖는 핵산 나노구조
JP2016160248A (ja) * 2015-03-05 2016-09-05 国立大学法人京都大学 糖誘導体、またはその塩、セレクチン結合剤、糖結合体、粒子状キャリア、および輸送方法
WO2016189532A1 (en) * 2015-05-26 2016-12-01 Ramot At Tel-Aviv University Ltd. Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
US9868828B2 (en) * 2015-06-23 2018-01-16 Amolifescience Co., Ltd. Defined three-dimensional microenvironment for stem cell
JP7125059B2 (ja) * 2016-02-05 2022-08-24 リグショシュピタレット ｕＰＡＲＡＰを標的にする抗体薬物複合体
WO2018026794A1 (en) * 2016-08-02 2018-02-08 Curirx Inc. Methods for the preparation of liposomes
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
ES2711669A1 (es) * 2017-11-02 2019-05-06 Univ Santiago Compostela Sistemas de liberacion de farmacos de acido polisialico y metodos
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
CN116670154A (zh) 2020-07-24 2023-08-29 总医院公司 增强的病毒样颗粒及使用其递送至细胞的方法
WO2022041760A1 (en) * 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
EP4604928A1 (en) * 2022-10-21 2025-08-27 Georgia Tech Research Corporation Lymphatic endothelial cell-specific lipid nanoparticle and uses thereof
EP4578463A1 (en) * 2023-12-29 2025-07-02 Oncomatryx Biopharma, S.L. Endo-180 targeted antibody-drug conjugates
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
CA1264668A (en) 1984-06-20 1990-01-23 Pieter R. Cullis Extrusion techniques for producing liposomes
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5225182A (en) 1991-10-31 1993-07-06 Sharma Yash P Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
KR940703846A (ko) 1991-12-24 1994-12-12 비. 린네 파샬 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides)
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US20050042647A1 (en) 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
CA2402613A1 (en) * 2000-03-29 2001-10-04 Igor Gonda Cationic liposomes
KR100872437B1 (ko) 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
ES2280826T5 (es) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
WO2004100759A2 (en) 2003-05-19 2004-11-25 Quark Biotech, Inc. Endo 180 receptor for diagnosis and treatment
CA2587337A1 (en) * 2004-11-19 2006-05-26 Novosom Ag Improvements in or relating to pharmaceutical compositions for local administration
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP2020992A2 (en) 2006-04-24 2009-02-11 The CBR Institute for Biomedical Research, Inc. Method of producing immunoliposomes and compositions thereof
AU2007243412A1 (en) 2006-04-25 2007-11-08 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
WO2008020435A2 (en) 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
CN103898110A (zh) 2007-10-03 2014-07-02 夸克制药公司 新siRNA结构
TWI373345B (en) * 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
CA2753388C (en) * 2009-03-23 2016-11-29 Quark Pharmaceuticals, Inc. Endo180 antibody to treat cancer and fibrotic disease
DK2504435T3 (da) 2009-11-26 2019-12-09 Quark Pharmaceuticals Inc Sirna-forbindelser omfattende terminale substitutioner
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
CN102091036A (zh) * 2011-01-10 2011-06-15 中国药科大学 一种含有抗肿瘤药物的复合脂质体及其制备方法和用途
CN102188713A (zh) * 2011-05-09 2011-09-21 中山大学 一种肝靶向药物组合物及其制备方法
CN102973506B (zh) * 2011-09-05 2015-06-03 中国科学院深圳先进技术研究院 阳离子脂质体及其制备方法

Similar Documents

Publication Publication Date Title
van der Koog et al. Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization
Kim et al. Engineering exosomes for pulmonary delivery of peptides and drugs to inflammatory lung cells by inhalation
Feng et al. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His
Zhang et al. Ligand size and conformation affect the behavior of nanoparticles coated with in vitro and in vivo protein corona
US8992984B1 (en) Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
Suk et al. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier
Varshney et al. Targeted delivery of microRNA‐199a‐3p using self‐assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice
JP2022058390A (ja) 治療的送達小胞
Zarschler et al. Diagnostic nanoparticle targeting of the EGF-receptor in complex biological conditions using single-domain antibodies
US20110269942A1 (en) Antibodies modified with hydrophobic molecule
US20170173169A1 (en) Cross-linked polymer modified nanoparticles
JP2012100677A5 (OSRAM)
JP2014532071A (ja) カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法
JP2014512409A5 (OSRAM)
WO2012094653A2 (en) Compositions and methods for macromolecular drug delivery
JP2022544289A (ja) Ｓｔａｔ６を標的とする細胞外小胞－ａｓｏ構築物
JP2022544288A (ja) ＣＥＢＰ／βを標的とする細胞外小胞－ＡＳＯ構築物
R. Beech et al. Mechanisms for targeted delivery of nanoparticles in cancer
Chen et al. Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG× CD20)
EP4615416A1 (en) Self-assembling lipid nanoparticles for targeted delivery of therapeutic agents
JP2019533677A (ja) 細胞傷害性粒子
US20130202687A1 (en) Lipid vectors delivering gene silencers
CN108883068A (zh) 使用紫杉烷的阳离子微脂体制剂、紫杉烷的非微脂体制剂和其他活性药剂合并治疗乳癌的方法
CN122028909A (zh) 用于主动靶向的具有非共价双功能结合物的脂质纳米颗粒
KR20220092557A (ko) 펩티드-나노입자 접합체